logo
Share SHARE
FONT-SIZE Plus   Neg

AVEO, Astellas Say Tivozanib Superior To Sorafenib In Advanced RCC - Quick Facts

AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) Tuesday said that tivozanib Phase 3 clinical trial demonstrated superiority over sorafenib in the primary endpoint of progression-free survival in patients with advanced renal cell carcinoma.

TIVO-1, a global, randomized Phase 3 clinical trial evaluated the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma. TIVO-1 is the first registration study in first-line renal cell carcinoma that is comparing an investigational agent against an approved VEGF therapy.

The companies noted that tivozanib demonstrated a well-tolerated safety profile consistent with the Phase 2 experience; the most commonly reported side effect was hypertension, a well established on-target and manageable effect of VEGFR inhibitors

Based on these data, AVEO and Astellas currently plan to submit for marketing approval of tivozanib in the US and Europe in 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Netflix has announced the new arrivals in its streaming video lineup in the month of December that include many Christmas-themed shows and films to choose from. The holiday season will also see some great movies disappearing from the platform. Shares of easyJet Plc were gaining around 6 percent in the morning trading in London after the airline reported higher revenues, traffic and capacity in its fiscal 2017, despite weak profit. Looking ahead, the company projects capacity growth in fiscal 2018. Following his twelve-day trip to Asia, President Donald Trump announced Monday the U.S. is putting North Korea back on a list of state sponsors of terrorism. Trump announced the move in comments ahead of a Cabinet meeting and said his administration would also be ramping up sanctions on North Korea.
comments powered by Disqus
Follow RTT